Stronger together? Boehringer and Mirati team to put first KRAS-KRAS combo in the clinic
Researchers are still waiting to see how much any of the vaunted KRAS drugs now in the clinic can, after decades of preclinical research and some early human studies, help patients. But while they do, two of the leading developers will look to see whether a KRAS-KRAS combo might pose a better shot than any KRAS alone.
Boehringer Ingelheim and Mirati have signed a collaboration to combine Mirati’s closely-watched lead KRAS inhibitor, MRTX849, in a clinical trial with the pan-KRAS blocker that Boehringer has quietly developed with high expectations behind their flashier contenders.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.